
    
      1. Compare progression-free survival (PFS) and overall survival (OS) of definitive
           radiochemotherapy versus(VS) neoadjuvant radiochemotherapy plus radical resection for
           esophageal cancer patients who down stage from inoperable to operable after neoadjuvant
           treatment;

        2. Compare the toxic and side effects of definitive radiochemotherapy versus neoadjuvant
           radiochemotherapy plus radical resection for esophageal cancer patients who achieved
           clinical complete remission after neoadjuvant treatment;

        3. Assess impact of definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus
           radical resection on quality of life of patients.

      Concurrent Radiochemotherapy: Radiotherapy, Intensity Modulation Radiation Therapy(IMRT),
      40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2), 1st/8th/15th/22nd day
    
  